Released on: January 7, 2008, 10:39 am

Press Release Author: GTCBIO

Industry: Pharmaceuticals

Press Release Summary: MONROVIA, CA - James Chafouleas, Director of Global Licensing
- Virology at Boehringer Ingelheim and Leigh Farrell, Vice President of Business
Development at Biota will give a joint presentation entitled "Making the Right Deal:
It's Not Just About the Money" at GTCbio's 5th Anti-Infectives Partnering &
Deal-Making Summit taking place on March 5-7 2008 in Philadelphia, PA.

Press Release Body:
FOR IMMEDIATE RELEASE


December 20, 2008

Joint Presentation from Boehringer Ingelheim and Biota at GTCbio's 5th
Anti-Infectives Partnering & Deal-Making Summit (March 5-7, 2008, Philadelphia, PA)

MONROVIA, CA - James Chafouleas, Director of Global Licensing - Virology at
Boehringer Ingelheim and Leigh Farrell, Vice President of Business Development at
Biota will give a joint presentation entitled "Making the Right Deal: It's Not Just
About the Money" at GTCbio's 5th Anti-Infectives Partnering & Deal-Making Summit
taking place on March 5-7 2008 in Philadelphia, PA.

In November 2006, Biota Holdings Limited (Biota), an Australian biotechnology
company signed a $102m collaboration and license agreement with Boehringer Ingelheim
for its discovery-stage HCV nucleoside analogue program. Biota's licensing strategy
for its HCV nucleoside program involved pursuing full contract negotiations with
multiple parties. Key drivers for Biota's selection of Boehringer Ingelheim were
Boehringer Ingelheim's expertise in the field of HCV, the cultural fit between the
scientists and management of both companies, and Boehringer Ingelheim's high-level
buy-in and strong record of good alliance management. The collaboration has been
operating productively for over twelve months. Dr. James Chafouleas, Director of
Global Licensing - Virology at Boehringer Ingelheim and Dr. Leigh Farrell, Vice
President of Business Development at Biota will present their respective strategies
for pursuing the deal and report on the alliance management process that has been
adopted to manage this long distance relationship.

The conference also features presentations from AstraZeneca, Eli Lilly and Company,
GlaxoSmithKline, Human Genome Sciences, Merck, Novartis, Wyeth and many more. The
full agenda is available online at www.gtcbio.com.

The 5th Anti-Infectives Partnering & Deal Making Summit is an infectious disease
partnering and business development conference that gives global biotechnology and
pharmaceutical companies an opportunity to network with high-level executives from
top pharma and various biotech/pharmaceutical companies, as well as explore
potential collaborations, and learn about relevant anti-infective issues and deals
that will affect the industry.

This event also provides a unique venue for attendees to learn about the
anti-infective business development trends, the infectious disease markets, and
novel technologies that shape up the industry. For more information, please visit
www.gtcbio.com.
ABOUT GTCbio
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical
industries. Our goal is to facilitate the exchange of biopharmaceutical and
biomedical intelligence between industry leaders, academic and government
organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company
founded in 2002.
Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax, infogtcbio@gtcbio.com


Web Site: http://

Contact Details: Contact: GTCBIO (626) 256-6405, (626) 256-6460 fax,
infogtcbio@gtcbio.com